Titlebook: New Approaches in Cancer Pharmacology: Drug Design and Development; Paul Workman (Chairman and Editor) Conference proceedings 1992 Springe

Coagulant

書目名稱New Approaches in Cancer Pharmacology: Drug Design and Development影響因子(影響力)




書目名稱New Approaches in Cancer Pharmacology: Drug Design and Development影響因子(影響力)學(xué)科排名




書目名稱New Approaches in Cancer Pharmacology: Drug Design and Development網(wǎng)絡(luò)公開度




書目名稱New Approaches in Cancer Pharmacology: Drug Design and Development網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱New Approaches in Cancer Pharmacology: Drug Design and Development被引頻次




書目名稱New Approaches in Cancer Pharmacology: Drug Design and Development被引頻次學(xué)科排名




書目名稱New Approaches in Cancer Pharmacology: Drug Design and Development年度引用




書目名稱New Approaches in Cancer Pharmacology: Drug Design and Development年度引用學(xué)科排名




書目名稱New Approaches in Cancer Pharmacology: Drug Design and Development讀者反饋




書目名稱New Approaches in Cancer Pharmacology: Drug Design and Development讀者反饋學(xué)科排名

脾氣暴躁的人

英寸

Ferritin

Prospects for Biological and Gene Therapies,om the outset. Despite the encouraging success of chemotherapy for a variety of rare tumour types, in the vast majority of human solid cancers such treatment has had little impact on survival. This is disappointing considering the tremendous efforts of the last 20 years.

Nonconformist

Conference proceedings 1992atment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly

灌溉

Antisense and Antigene Oligonucleotides Targeted to Oncogenes,tion of tumour-suppressor genes represent new strategies that should lead i) to a better understanding of the different steps involved in tumourigenesis, and ii) to the development of new therapeutic approaches.

llibretto

冰雹

978-3-642-77876-6Springer-Verlag Berlin Heidelberg 1992

Notorious

抱負(fù)

Current Strategies in Anticancer Drug Discovery Within the EORTC,Advances in the treatment of malignant diseases have been limited by our failure to identify unique biochemical and/or biological properties which are able to clearly distinguish cancer cells from the normal cell population. Consequently, currently available anticancer agents lack tumour selectivity and possess a narrow therapeutic index [1].